Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy
Status:
Not yet recruiting
Trial end date:
2023-07-11
Target enrollment:
Participant gender:
Summary
The study of LVGN6051-201 is designed to use a bridging dose escalation to quickly establish
the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as
the recommended Phase 2 dose(s) (RP2D) of LVGN6051, both as a single agent (monotherapy) and
in combination with a fixed dose of anti-PD-1 antibody (Pembrolizumab) in the treatment of
advanced or metastatic malignancy.